RxDoctor Payments Data

Anil Patel, MD

Internal Medicine · Hempstead, NYNPI 1497739635

Payments from drug & device makers

$5,472in general payments, 2019–2025

Across 240 payments — averaging $22.80 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$1K
  • AstraZeneca$1K
  • Sanofi-aventis U.S. LLC$637
  • Merck$501
  • AbbVie$461
  • GSK$333
  • plus $1K from 15 others

What the payments were for

  • Food & beverage$5,472100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,472 in reported general payments places this provider in the 85th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$173,491
Medicare patients
140
Services billed
2,845

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide95$111,250
BiktarvyBictegrav/Emtricit/Tenofov Ala19$76,010
JanuviaSitagliptin Phosphate42$59,131
EliquisApixaban47$57,812
FarxigaDapagliflozin Propanediol39$54,807
LinzessLinaclotide47$40,268
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$39,264
JardianceEmpagliflozin25$33,259
EntrestoSacubitril/Valsartan20$31,950
RybelsusSemaglutide11$28,053
XareltoRivaroxaban19$26,843
Breo ElliptaFluticasone/Vilanterol43$20,847
ZenpepLipase/Protease/Amylase11$16,882
Toujeo Max SolostarInsulin Glargine,hum.Rec.Anlog15$15,759
TradjentaLinagliptin14$14,860

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Rybelsus$1,158$139,302106 claims
MerckJanuvia, Janumet$501$73,77655 claims
AstraZenecaFarxiga, Breztri Aerosphere$1,025$63,11952 claims
GSKTrelegy Ellipta, Breo Ellipta$333$60,11091 claims
PfizerEliquis$123$57,81247 claims
Boehringer IngelheimJardiance, Tradjenta$125$48,11939 claims
AbbVieLinzess$461$40,26847 claims
NovartisEntresto$180$31,95020 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Hempstead

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →